Displaying 1321 - 1340 of 1535
Mylan Laboratories, Inc., Cambrex Corporation, Profarmaco S.R.I., and Gyma Laboratories of America, Inc.
Complaint filed in the U.S. District Court for the District of Columbia charged Mylan with restraint of trade, monopolization and conspiracy to monopolize the market for two generic drugs used to treat anxiety, lorazepam and clorazepate, through exclusive dealing arrangements. The Commission alleged that Mylan, Gyma Laboratories of America, Inc., Cambrex Corporation and Profarmaco S.R.L. conspired to deny Mylan’s competitors ingredients necessary to manufacture lorazepam and 40 clorazepate. The complaint sought consumer redress of at least $120 million and to enjoin the alleged illegal exclusive licensing agreements. The district court upheld the Commission’s authority to seek restitution in antitrust injunction actions under Section 13(b). The Commission approved a $100 million settlement. The opinion settled Commission concerns that Mylan, Gyma Laboratories of America, Inc., Cambrex Corporation and Profarmaco S.R.L. conspired to deny Mylan’s competitors ingredients necessary to manufacture lorazepam and 40 clorazepate. On Feburary 1, 2002, the court granted approval to a plan of distribution to injured consumers who paid the increased prices and state agencies, including Medicaid programs, that purchased the drugs while the illegal agreements were in effect. The funds were distributed by the states.
Antitrust Issues in Settlement of Pharmaceutical Patent Disputes
Department of Justice Sues Boston Scientific Corp. Seeking Civil Penalties and Other Relief for Violations of 1995 FTC Order
Fairbanks, Alaska Physician's Group to Settle FTC Charges Price-Fixing and Concerted Refusals to Deal with Health Plans
Appeals Court Upholds FTC Ruling; Doan's Must Include Corrective Message in Future Advertising and Labeling
Pfizer Inc., and Warner-Lambert Company
Final consent order permits Pfizer’s merger with Warner-Lambert Company and requires divestitures in several pharmaceutical markets including: Pfizer’s RID brand of head lice treatment; Pfizer’s antidepressant drug, Celexa; Warner’s Cognex, a drug used in the treatment of Alzheimer’s disease; and assets relating to the Epidermal Growth Factor receptor tryosine kinase inhibitor - drugs under development to treat solid cancerous tumors such as head and neck, non-small cell lung, breast, ovarian, pancreas and colorectal cancers.
Establishing Pharmacy Network as Proposed Not Likely to Restrain Competition, FTC Staff Advises
Statement of Richard G. Parker, Director, FTC Bureau of Competition
Colegio de Cirujanos Dentistas de Puerto Rico
The dental association with a membership of more than 1800 dentists practicing in Puerto Rico agreed not to encourage its members to enter into agreements that set or fixed the fees charged or terms and conditions under which dentists would deal with health insurance plans or other payers in an attempt to obtain higher reimbursement rates for dental services.
Armstrong Surgical Center, Inc., Petitioner v. Armsrong County Memorial Hospital, et al.
Riddles and Lessons from the Prescription Drug Wars: Antitrust Implications of Certain Types of Agreements Involving Intellectual Property
Abbott Laboratories, In the Matter of
Abbott and Geneva Pharmaceuticals settled charges that the two firms entered into an illegal agreement to stop the marketing and development of a competing generic drug. According to the complaint, Abbott, manufacturer of Hytrin – the brand name for terazosin HCL, a prescription drug used to treat hypertension and benign prostatic hyperplasia, entered into an agreement with Geneva Pharmaceuticals whereby Abbott would pay Geneva millions of dollars not to market a generic version of Hytrin. The orders bars Abbott and Geneva, among other things, from entering into agreements in which a generic company agrees with a manufacturer of a branded drug to delay or stop the production of a competing drug.
Texas Surgeons, P.A.; Austin Surgical Clinic Association, P.A.; Central Texas Surgical Associates, P.A.; Surgical Associates of Austin, P.A.; Austin Surgeons, P.L.L.C.; Bruce McDonald & Associates, P.L.L.C.; and Capital Surgeons Group, P.L.L.C
General surgeons and six competing general surgery practice groups in the Austin, Texas area settled charges that they collectively refused to deal with two health plans, forcing the plans to accept the surgeons’ demands to raise surgical rates.
Wisconsin Chiropractic Association, The, and Russell A. Leonard, In the Matter of
The Wisconsin Chiropractic Association and its executive director, Russell A. Leonard, settled charges that they conspired to fix the prices for chiropractic goods and services and to boycott third party payers in an attempt to obtain higher reimbursement rates for services and contracts in the La Crosse, Wisconsin area.
Puerto Rico Dental Association Agrees to Settle FTC Charges of Price Fixing, Boycotting Providers, and Restraining Truthful Advertising by Members
FTC Charges Drug Manufacturers with Stifling Competition in Two Prescription Drug Markets
Wisconsin Chiropractic Association and Its Director Agree to Settle FTC Charges of Price-Fixing
Tenet Healthcare Corporation, Inc., and Poplar Bluff Physicians Group, Inc. d/b/a Doctors Regional Medical Center, FTC and State of Missouri
The FTC authorized its staff to file a motion for a preliminary injunction to block the proposed acquisition of Doctors Regional Medical Center in Poplar Bluff, Missouri. On July 30, 1998, the U.S. District Court for the Eastern District of Missouri granted the Commission's motion for the injunction. Tenet filed a notice of appeal in the Eighth Circuit on August 10, 1998. An administrative complaint was issued August 20, 1998 charging that the proposed merger of the only two general hospitals in Poplar Bluff would not only eliminate price, cost and quality competition but would also put consumers at risk of paying more for health care. In December 1999, the Commission dismissed the administrative complaint after the Eighth Circuit reversed the district court's decision and denied Commission’s petition for a rehearing en banc.
SNIA S.p.A, In the Matter of
Final order settles charges that Sorin Biomedica S.p.A.'s acquisition of COBE Cardiovascular, Inc. would eliminate competition in the United states market for research, development, manufacture and sale of heart-lung machines. The order permits the acquisition and requires the divestiture of COBE's heart-lung machine business to Baxter Healthcare Corporation
Displaying 1321 - 1340 of 1535